The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) with new-generation prostheses remains debated. This systematic review analyses the incidence of PPI after TAVI with new-generation devices and evaluates the electrical, anatomical, and procedural factors associated with PPI. In addition, the incidence of PPI after TAVI with early generation prostheses was reviewed for comparison. 
Introduction
Technological developments in transcatheter aortic valve implantation (TAVI) have facilitated the procedure and reduced significantly the incidence of vascular complications and paravalvular regurgitation, leading to an exponential increase of this therapy in patients with symptomatic severe aortic stenosis and contraindications or high risk for surgical aortic valve replacement and, recently, in patients with
intermediate operative risk. 1, 2 However, there remain some concerns when considering TAVI for low operative risk patients. Compared with surgical aortic valve replacement, TAVI has been associated with higher rates of permanent pacemaker implantation (PPI) after the procedure. 3, 4 Current evidence indicates that several electrical, anatomical, and procedural factors are associated with the need for PPI after TAVI. 5, 6 For early-generation TAVI prostheses (Figure 1 ), age and pre-existent and procedure-induced conduction abnormalities and the use of a self-expandable prosthesis were the factors significantly associated with the increased risk of PPI. 5, 6 However, the incidence of PPI when using new-generation prostheses have not been extensively evaluated ( Figure 1 ). In addition, the factors associated with the increased risk of PPI with these new devices have not been studied. Bearing in mind that the indication for TAVI is expanding towards younger and lower surgical risk patients, it is important to understand the patient and procedural characteristics associated with post-procedural PPI.
In this systematic review, the incidence of PPI across different newgeneration TAVI prostheses was analysed and compared with the incidence of PPI with the use of early-generation devices (as reported in the literature). [6] [7] [8] In addition, the various electrical, anatomical, and procedural characteristics that are associated with PPI with the newgeneration devices were reviewed.
Methods

Search strategy and selection criteria
This systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. 9 Studies reporting on the rate of PPI after TAVI with new-generation prostheses ( D.) independently reviewed the titles and abstracts of the original articles obtained in the initial search and selected the articles that reported on the PPI rate after implantation of new-generation transcatheter aortic valve prostheses, included > _100 patients, and were published in English in a peer-reviewed journal. If considered eligible, the full article was scrutinized for inclusion, and the reference list and articles citing the included study (as provided by Google Scholar) were reviewed. To minimize the potential bias introduced by the experience and learning curve, studies including <100 patients treated with a new-generation transcatheter valve prosthesis, and studies that did not report on the PPI rate (or that clustered the PPI rate of earlier and new-generation prostheses) were excluded. In addition, for studies with overlapping patient populations, we selected the study with the largest population reporting on the PPI rate. Finally, abstracts and unpublished data presented at major international cardiology congresses were not considered for this analysis. The final search ended on 1 November 2017.
To compare the post-procedural PPI incidence between new and early-generation (Edwards SAPIEN, SAPIEN XT, and Medtronic CoreValve) prostheses, recent systematic reviews and meta-analyses investigating the occurrence of a PPI after early-generation TAVI prostheses were considered. [6] [7] [8] In addition, studies from the initial PubMed database search were rescreened for this specific purpose to find the possible studies that had not been included in the meta-analyses. [6] [7] [8] Studies evaluating the incidence of PPI after early-generation prostheses were included by the same selection criteria as for the studies on new-generation prostheses.
Data extraction
For each original article included in the systematic review, the following characteristics were extracted: year of publication, design of the study, number of patients, age, gender, operative risk score [logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), or the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score], baseline heart rhythm (sinus rhythm, atrial fibrillation, and pacemaker rhythm), time of follow-up, and number of PPI after TAVI. In addition, the PPI rates that included pacemaker implantation prior to TAVI in the calculation were carefully scrutinized. Furthermore, data on several electrical, anatomical, and procedural factors that may influence the PPI rate were evaluated. Specifically, the electrical factors included the presence of different pre-existent conduction abnormalities: atrial fibrillation, atrioventricular (AV) block, PR interval duration, and right or left bundle branch block. The anatomical factors included the association between the calcification burden of the landing zone [left ventricular outflow tract (LVOT) and aortic valve] and the length of the membranous interventricular septum vs. the need for PPI. Finally, the procedural factors included the implantation depth of the device, coaxiality of the implantation, prosthesis oversizing, and the need for reballooning.
Statistical analysis
Categorical data are presented as frequencies and percentages.
Frequencies of post-TAVI PPI are presented in a histogram using GraphPad Prism software (version 7.00, GraphPad Software, La Jolla, CA, USA). According to the post-TAVI PPI rates, quintiles were calculated using SPSS software (version 23.0; IBM Corp., Armonk, NY, USA). The studies within the highest and the lowest quintiles were evaluated and compared.
Results
After screening the titles and abstracts of 1406 original articles that were identified in the first search, 348 articles were examined for full text. Finally, 40 studies reporting on PPI after new-generation TAVI prostheses were included ( Figure 2A) . The characteristics of the study populations stratified according to the type of new-generation TAVI prosthesis are presented in Supplementary material online, Table S1A 4,10-48 and the frequencies of post-TAVI PPI are plotted in Figure 3 . 49 Naber et al. 32 described the largest patient population treated with this device (n = 250) in the prospective, European multicentre registry and reported a post-TAVI PPI rate of 12.0%. The CoreValve Evolut R prosthesis was evaluated in 8 studies, including a total of 6017 patients. Post-TAVI PPI rates varied from 14.7%, as reported by Kalra et al. 33 to 26.7% in the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial. 4 Data from the latest report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry revealed a post-TAVI PPI rate of 18.3% in 3810 patients who were treated with this device. 34 Reported TAVI-PPI intervals were 2-3 days. 33, 35 The Portico prosthesis was evaluated in a prospective, multicentre study including 222 patients, and the reported incidence of PPI after TAVI was 13.5%. 36 Only one study including patients treated with the JenaValve system fulfilled the inclusion criteria. 37 Silaschi et al., 37 in their prospective multicentre study, showed a post-TAVI PPI rate of 14.4%. Finally, data from 795 patients treated with the ACURATE transcatheter heart valve system were evaluated. 38, 39, 47, 50 Toggweiler et al. 47 reported a post-TAVI PPI rate of 2.3% in 175 patients. In the studies by Börgermann et al. 38 (n = 500) and Hamm et al. 39 (n = 120), the PPI rates were 10.2% and 9.6%, respectively. 
To compare these incidences with those reported by studies including only early-generation devices, the studies included in recent systematic reviews and meta-analyses were scrutinized. [6] [7] [8] In addition, from the initial literature search, four additional studies not included in the systematic reviews and meta-analyses were included in this analysis. [50] [51] [52] [53] Twenty-seven studies evaluating the PPI incidence with the use of early-generation TAVI prostheses fulfilled the selection criteria and were finally included ( Figure 2B , see Supplementary material online, Table S1B ). 40, For the earlygeneration SAPIEN devices, the post-TAVI PPI rate ranged from 2.3% in the PARTNER EU trial (n = 130) 54 to 17.3% in the randomized controlled CHOICE trial (n = 121 SAPIEN XT vs. n = 120 CoreValve). 50 However, this PPI rate increased up to 28 .2% in a single-centre study, including 110 patients without a previous pacemaker who were treated with early-generation SAPIEN devices. 55 Regarding the early generation of the CoreValve, the PPI rate ranged from 16 .3% in the Italian CoreValve Registry 56 to 37.7% in the CHOICE trial. 50 Comparison of studies with high vs low permanent pacemaker implantation rate after new-generation prostheses
The studies were categorized according to the post-TAVI PPI rate quintiles, and the studies within the lowest (<12.1%) and the highest (>26.0%) quintile were compared (Table 1) . 46 .3%, P < 0.001). The proportion of patients who had atrial fibrillation was lower in the lowest PPI quintile group (29.3% vs. 31 .9%, P = 0.029). No other significant differences were observed.
Studies analysing factors associated with permanent pacemaker implantation following transcatheter aortic valve implantation with new-generation prostheses
Several studies investigated the factors associated with PPI after newgeneration TAVI prosthesis ( Table 2) . 12, [15] [16] [17] [18] [19] [21] [22] [23] 35, 40 Among the several electrical factors that could influence the PPI rate, multivariate analyses evaluating the SAPIEN 3 valve identified the presence of preprocedural conduction abnormalities such as the right bundle branch block (RBBB), [16] [17] [18] [19] 40 prolonged PR interval, 16, 40 and atrial fibrillation 17 to be associated with post-procedural PPI. For the Lotus valve, Dumonteil et al. 23 showed that RBBB and first-degree AV block were independent electrical determinants of post-procedural PPI. Similarly, for the CoreValve Evolut R, Gomes et al. 35 found that pre-existent RBBB was the electrical factor independently associated with the need for PPI.
Regarding the anatomical factors potentially influencing the need for PPI, data from computed tomography scans performed in patients treated with the SAPIEN 3 showed that the amount of calcification in the device landing zone was independently associated with post-TAVI PPI. 18, 19 Similarly, for the Lotus valve, Dumonteil et al. 23 showed an independent association between the amount of LVOT calcification as assessed with CT and increased risk of post-TAVI PPI. Furthermore, among the various procedural determinants, the implantation depth of the SAPIEN 3 was identified as an independent correlate of post-procedural PPI in several studies. 15, [17] [18] [19] 21 Data from the REPRISE II study, including the extended cohort, showed that >10% overstretch of the LVOT was an independent procedural factor associated with increased post-TAVI PPI when a Lotus valve was implanted. 23 In contrast, a deep implantation of the Louts valve (>5 mm deep into the LVOT) was associated with increased risk of PPI. 23 When using the CoreValve Evolut R, Gomes et al. 35 also
showed that the implantation depth was a procedural factor independently associated with the need for PPI. The studies investigating the factors associated with PPI after earlygeneration TAVI prosthesis are provided in Supplementary material online, Table S2 . 
Discussion
In this systematic review, including 17 139 patients treated with newgeneration TAVI prostheses, a wide range of post-TAVI PPI rates across various prostheses has been shown. The factors influencing this wide variability have not been fully elucidated, but the available evidence suggests that various electrical, anatomical, and procedural factors may explain these findings. Furthermore, it is important to note that some patients had a pacemaker prior to TAVI and the indication for PPI after TAVI varied significantly across the studies and not always fulfilled prevailing recommendations. 75 Compared with early-generation devices, the PPI rates remain low with the balloonexpandable prostheses, whereas they have reduced with the newgeneration of self-expandable CoreValve systems.
Electrical factors associated with posttranscatheter aortic valve implantation permanent pacemaker implantation
The aortic valve is in close anatomical relationship with the AV node and left bundle branch. The AV node is located in the right atrium in proximity to the septal part of the tricuspid valve and to the muscular ventricular septum in continuity with the aortic valve cusps. 76 At a lower level of the conduction system, the LVOT is in close relationship with the left bundle branch. 76 Direct mechanical trauma or compression of the AV node or the left bundle branch by balloon dilatation or prosthesis implantation can cause a high-degree AV block or LBBB during or after TAVI. 6 Pre-existing damage of the conduction system, such as the RBBB, increases the risk of advanced conduction abnormalities after TAVI requiring PPI. Particularly, the presence of RBBB has been independently associated with the need for PPI in several studies using the SAPIEN 3, [16] [17] [18] [19] 40 Lotus, 23 and the CoreValve Evolut R 35 prostheses. Auffret et al., 77 in their multicentre study including 3527 patients treated with TAVI, showed that 10% of the patients had pre-existing RBBB. The presence of RBBB at discharge was associated with the composite endpoint of sudden cardiac death and PPI with a hazard ratio of 2. 68 . Electrophysiological studies performed after TAVI have shown damage of the AV node, the His, and the infra-His system. 78 complete AV block during the procedure and postoperative high-degree AV block were the only factors associated with the need for PPI at follow-up, whereas the serial measurements of the HV interval could not predict the need for PPI. 80 Compression of the left bundle branch by the prosthesis or periprocedural oedema of the LVOT in patients with pre-existent RBBB causes complete AV block.
However, it remains difficult to predict whether the AV block will be permanent or transitory. When the damage of the left bundle branch is caused by oedema of the interventricular septum resulting from oversized balloons, the function of the left bundle branch may be recovered upon resolution of the oedema. However, there is no method to image the presence of oedema after TAVI and to predict the recovery of the left bundle branch function because the artefacts that the prosthetic frame causes on cardiovascular magnetic resonance preclude reliable assessment of this phenomenon. In addition, atrial fibrillation has been independently associated with the need for PPI in patients treated with the SAPIEN 3 (odds ratio 3.996, 95% confidence interval 1.567-10.192 ). 17 In patients with atrial fibrillation treated with TAVI, Tovia-Brodie et al. 79 used a heart rate <100 b.p.m.
as a marker of intrinsic AV node dysfunction and demonstrated that 50% of these patients may show infranodal conduction disturbances on electrophysiological study.
Anatomical factors associated with permanent pacemaker implantation after transcatheter aortic valve implantation
The presence and distribution of calcifications underneath the aortic annulus plane and affecting the interventricular septum (landing zone) are the anatomical factors that have been associated with the need for PPI. 18, 19 Computed tomography used to size the aortic annulus and select the prosthesis size provides important information in this regard. Mauri et al. 19 found a strong association between dense calcification in the LVOT under the left and right coronary cusps and the need for PPI after TAVI using the SAPIEN 3 valve. An asymmetrical calcium distribution may result in an oblique expansion of the prosthesis and uneven distribution of the mechanical stress on the AV conduction system. In patients undergoing TAVI with the Lotus valve, Dumonteil et al. 23 showed that an increasing total volume of calcium in the LVOT was associated with the high risk of PPI (odds ratio 1.80 per 100 mm 3 increase, 95% confidence interval 1.03-3.14). These findings suggest that it is important to assess the presence and distribution of the calcifications of the landing zone because careful procedural planning may reduce the risk of conduction abnormalities requiring PPI. By controlling the procedural factors associated with PPI after TAVI (modifiable factors), the PPI rate could decrease.
Procedural factors associated with permanent pacemaker implantation after transcatheter aortic valve implantation
Implantation depth into the LVOT is strongly associated with increased risk of PPI after TAVI, regardless of the prosthesis used. For the SAPIEN 3 valve, Mauri et al. 19 showed that when >25.5% of the prosthesis frame is implanted into the ventricular side, the odds ratio of PPI was 15.7 (95% confidence interval 5.7-43.5 ) and the rate of PPI decreased from 19.2% to 9.2% when < _21% of the prosthesis frame was implanted into the ventricular side (P = 0.038). Similarly, when using the CoreValve Evolut R, Gomes et al. 35 demonstrated that there is an independent association between the implantation depth and the PPI rate. In addition, procedural overstretching of the LVOT resulting in more pressure on the surrounding conduction system appeared to be an independent predictor for a PPI after Lotus valve implantation in the 249 patients described by Dumonteil et al.
23
The damage of the AV node and His bundle can occur as well during balloon valvuloplasty. 78 In a series of 18 patients treated with the CoreValve system undergoing electrophysiological study before and after TAVI, Rubín et al. 78 showed that the damage of the conduction system occurred during the balloon dilation of the valve in 43% of the patients. With the new TAVI prostheses, Abramowitz et al. 41 demonstrated lower rate of PPI among patients in whom balloon dilation was not performed (11.5% vs. 14.3%). In addition, Toggweiler et al. 47 hypothesized that the low PPI rate with the use of the ACURATE transcatheter heart valve system may be attributable to the relative low radial force that the inflow portion of this frame exerts on the surrounding AV conduction system. Furthermore, pre-and postdilation occurred with balloons 1-2 mm smaller than the aortic annulus diameter, which may result in less damage of the conduction system. 47 Future directions: integration of pre-and periprocedural data A wide range of PPI rates across the studies reflects the heterogeneous populations and procedural characteristics and therefore limits generalizability of the results. However, the results of this study suggest that careful pre-procedural evaluation of pre-existing conduction abnormalities and location of LVOT calcifications may assist procedural planning, particularly in terms of optimal prosthesis implantation depth into the LVOT, the need for balloon valvuloplasty, the balloon size, and the prosthesis type to minimize the risk of PPI. For example, in patients with pre-existing RBBB, atrial fibrillation and severe heterogeneous distribution of LVOT calcifications, a high prosthesis implant may reduce the risk of PPI. Understanding the design and conformation of the prostheses once deployed is also important to reduce the risk of PPI. The SAPIEN 3 prosthesis has a larger stent frame, but it also shortens significantly more from the ventricular side than the previous generations. In the SAPIEN 3 European approval trial, the recommendations on the positioning and deployment of the prostheses were slightly altered from those of the PARTNER II trial, and the central marker of the prosthesis should be positioned proximally to the base of the aortic cusps instead of placing it below the insertion point of the leaflets. 10, 11 This manoeuvre resulted in a significant decrease in PPI rate (from 13.3% to 4.0%).
In addition, it would be important to study the time course of the conduction abnormalities induced after TAVI. Several studies have shown that these conduction disturbances are not permanent and patients may not be pacemaker dependent during follow-up. [81] [82] [83] The study by Toggweiler et al. 84 , including 1064 patients treated with early-and new-generation devices, has shown that delayed highdegree AV block may occur up to 8 days post-procedure in 7% of
patients. However, patients without conduction disorders immediately after TAVI did not show any delayed high-degree AV block, and therefore, the need for ECG monitoring beyond 48 h in those patients may not be needed. 84 Currently, the prognostic implications for a PPI after TAVI are conflicting. The evidence arises mainly from early-generation prostheses. Pooled data from 9785 patients undergoing TAVI in the USA showed an increased 1-year mortality among patients who received a PPI after TAVI (hazard ratio 1.31 , 95% confidence interval 1.09-1.58). 5 In contrast, Urena et al. 85 observed in 1556 patients that a PPI after TAVI has been associated with a lower risk of sudden cardiac death (hazard ratio 0.31, 95% confidence interval 0.11-0.85). In addition, a recent meta-analysis including 20 287 TAVI patients also did not observe an increased risk for all-cause and cardiovascular mortality in patients treated with a PPI. 8 Of importance, PPI has been also associated with a significant decrease in the left ventricular function, which may impact on survival at long-term follow-up. 5, 8, 85 For the newgeneration TAVI devices, data regarding mortality or left ventricular function after a PPI are scarce. For the SAPIEN 3 prosthesis, Husser et al. 17 observed a 30-day mortality of 3% in 34 patients (16.3% of the total 208 pacemaker naive patient cohort) who received a PPI, and this mortality rate was not significantly higher compared with the patients not treated with a PPI (P = 0.163). 17 For the CoreValve Evolut R, Reardon et al. 4 reported from the SURTAVI trial that there were no differences in 24-month mortality among patients who required a PPI compared with the counterparts who did not need PPI. However, this analysis involved both patients treated with the first-generation CoreValve (n = 724) as with the CoreValve Evolut R (n = 139). 4 
Conclusions
The rate of PPI after TAVI with new-generation devices is highly variable and appears influenced by electrical factors (pre-existent conduction abnormalities), anatomical factors (calcification of the LVOT), and procedural factors (balloon valvuloplasty and depth of implantation). Specific recommendations for implantation of each prosthesis, taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors, may be needed to reduce the risk of PPI. Furthermore, additional data on the time course of new-onset conduction abnormalities may help to refine the indication for PPI.
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